Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kailera TherapeuticsKLRA +2.24%11 Return-on-Tangible-Asset is -34.21% as of Dec. 2025. GuruFocus rates KLRA with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 1,415 Biotechnology companies, Kailera Therapeutics ranks better than 51.45% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Kailera Therapeutics's annualizedNet Income for the quarter that ended in Dec. 2025 was $-148.96 Mil. Kailera Therapeutics's average total tangible assets for the quarter that ended in Dec. 2025 was $435.37 Mil. Therefore, Kailera Therapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -34.21%.
The historical rank and industry rank for Kailera Therapeutics's Return-on-Tangible-Asset or its related term are showing as below:
KLRA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -34.21 Med: -34.21 Max: -34.21
Current: -34.21
During the past 2 years, Kailera Therapeutics's highest Return-on-Tangible-Asset was -34.21%. The lowest was -34.21%. And the median was -34.21%.
KLRA's Return-on-Tangible-Asset is ranked better than 51.45% of 1415
companies
in the Biotechnology industry
Industry Median: -35.49
vs KLRA: -34.21
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Kailera Therapeutics Return-on-Tangible-Asset Related Terms
Kailera Therapeutics Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Kailera Therapeutics's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KLRA vs VCEL, NUVB, IOVA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Kailera Therapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kailera Therapeutics Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kailera Therapeutics's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Kailera Therapeutics's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -34.21% mean?
Kailera Therapeutics (KLRA) has a Return-on-Tangible-Asset of -34.21% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kailera Therapeutics and its competitors. According to the industry distribution chart, Kailera Therapeutics ranks #687 out of 1415 companies in the Biotechnology industry, placing it in the top 48.6%.
Is Kailera Therapeutics' Return-on-Tangible-Asset too high?
Kailera Therapeutics' current Return-on-Tangible-Asset is -34.21%. Based on the distribution chart, Kailera Therapeutics ranks #687 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kailera Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' Return-on-Tangible-Asset compare to VCEL and NUVB?
According to the Biotechnology industry distribution chart, Kailera Therapeutics ranks #687 out of 1415 companies for Return-on-Tangible-Asset. This puts Kailera Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Kailera Therapeutics and its competitors. Kailera Therapeutics's current Return-on-Tangible-Asset is -34.21%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current Return-on-Tangible-Asset of -34.21%. The current Return-on-Tangible-Asset is -34.21%. Kailera Therapeutics' overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current Return-on-Tangible-Asset is -34.21% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
11GF Score
Get the complete analysis for KLRA
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLRA has been successfully added to your 
